Simplify Logo
Roche

Roche

Global pharmaceuticals and diagnostics company

Associate Finance Manager

Full-Time
$140.2k - $150.8k/yr

+ Annual bonus

Mid
Master's
Indianapolis, IN, USA
Hybrid

Up to 2 days of telecommuting per week.

About the job

Requirements
  • A Master's degree or foreign equivalent in Finance, Business, or a related field.
  • At least 4 years of experience in the job offered or a related Financial Planning and Analysis position.
  • At least 3 years of experience with accounting knowledge and financial statement analysis, including supporting month-end close, performing reconciliations and integrity checks, and preparing monthly management reporting in a multinational environment across time zones.
  • At least 3 years of experience with forecasting, budgeting, and performance management, including leading forecasting processes, coordinating cross-functional inputs, validating assumptions, and preparing narrative drivers and variance explanations for senior leadership review.
  • At least 3 years of experience implementing data analysis and automation tools, including advanced Excel with VBA or macros and emerging artificial intelligence-enabled tools.
  • At least 3 years of experience with finance business partnering and executive communication, including building executive reports and presentation decks and translating complex financial performance into actionable insights.
  • At least 3 years of experience with financial modeling and profitability analytics, including driver-based profitability and performance modeling and revenue and profit-and-loss variance drivers.
  • At least 3 years of experience with headcount and resource planning analytics, including full-time-equivalent reporting and headcount trend analysis to support resource allocation decisions.
  • At least 3 years of experience with financial reporting governance and internal controls, including establishing reporting processes, defining standard metrics, documenting standard operating procedures, and ensuring data integrity and compliance with internal standards.
  • At least 3 years of experience with enterprise finance systems and data structures, including enterprise resource planning, consolidation, and planning or reporting environments such as SAP or comparable enterprise finance platforms, and interpreting system outputs for management reporting.
Responsibilities
  • Utilize, synthesize, and integrate confidential financial and operational datasets, including profit-and-loss, balance sheet, cash flow, headcount and full-time-equivalent, sales, and expense drivers, to generate insights that guide results and strategy and help senior decision makers identify value-adding opportunities.
  • Apply internal protocols and standard operating procedures to execute annual business planning, monthly forecasting, periodic performance reporting, and month-end close activities.
  • Establish and maintain financial reporting systems, processes, and internal controls, including data validation, reconciliations, variance analysis, and integrity checks, to ensure reliability and compliance with Roche standards for financial statements and management information.
  • Develop and maintain analytics, insights, and financial modeling tools to support analysis of sales drivers, price and volume, cost of goods sold, and headcount trends.
  • Prepare executive reports and presentation decks for monthly United States Leadership Team meetings.
  • Lead local forecasting and Monthly Outlook cycles by coordinating organizational inputs, validating assumptions, preparing narratives and reporting on drivers and variances, and delivering consolidated forecasts and models for the United States Leadership Team.
  • Integrate technology and automation into insight-generation processes by automating recurring reporting and commentary collection, developing standard templates, training stakeholders, scaling expertise for future efforts, and streamlining processes across the organization.
  • Partner with global finance stakeholders, including Strategic Finance, the Enterprise Center of Excellence, and regional and global finance teams, and with senior leaders to align on processes and validate assumptions and performance drivers.
  • Support strategic and operational decision-making across time zones.
  • Provide finance business partnering support to enabling functions by advising on budgets, forecasts, resource planning, and performance tracking.

About the company

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% at constant exchange rates; core profit rose 10%.
  • FDA cleared Elecsys pTau217 on August 24, 2026, unlocking Alzheimer testing at scale.
  • Tam-Peli’s 54% death-risk reduction and global phase III plans strengthen oncology growth.

What critics are saying

  • Biocon’s Perjeta biosimilar lawsuit in New Jersey threatens Herceptin-like erosion by 2027.
  • Genentech disclosed 2026 layoffs, signaling ongoing restructuring and stalled internal productivity.
  • Swiss franc strength cut H1 2026 reported sales 2%, pressuring earnings translation again.

What makes Roche unique

  • Roche’s 4,500 US cobas instruments make Elecsys pTau217 instantly scalable.
  • Roche pairs pharmaceuticals and diagnostics, creating bundled disease franchises competitors cannot match.
  • Genentech gives Roche deep biologics R&D and patented oncology manufacturing depth.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Yahoo Finance
Sep 13th, 2026
Roche's Tam-Peli cuts death risk by 54% in Chinese SCLC trial, global phase III studies planned

Roche's collaborator MediLink has announced positive phase III results for tambotatug pelitecan (Tam-Peli) in Chinese patients with relapsed small-cell lung cancer. The TAISHAN-302 trial showed Tam-Peli reduced the risk of death by 54% compared to topotecan, with median overall survival of 13.3 versus 9.4 months. The antibody-drug conjugate also demonstrated superior progression-free survival (7.4 versus 2.8 months) and objective response rates (59.1% versus 9.7%). China's National Medical Products Administration has accepted the New Drug Application for filing. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, with plans to rapidly initiate global trials. The therapy has received Breakthrough Therapy Designations from both the US FDA and China CDE for relapsed small-cell lung cancer.

World Today News
Sep 8th, 2026
Tempus AI raises $600M to scale AI-enhanced liquid biopsy platform for cancer recurrence detection

Tempus AI has raised $600 million in Series C funding to scale its machine learning platform for cancer recurrence detection through liquid biopsies. The investment was led by SoftBank Vision Fund 2, with participation from Roche and Merck. Phase II trial data showed the AI-enhanced liquid biopsy analysis reduced false-negative results by 37% compared to conventional methods. The platform uses deep learning algorithms trained on over 12,000 genomic profiles to identify circulating tumour DNA fragments shed by residual cancer cells. A 2025 Nature Medicine study reported the system achieved 92% specificity in detecting minimal residual disease across breast, lung, and colorectal cancers. According to SEC filings, 45% of funds will support FDA pre-market approval trials, whilst 30% will fund global expansion into EU and APAC markets.

Yahoo Finance
Sep 1st, 2026
Roche commits $75M upfront in blood cancer deal worth up to $1.53B

Roche has committed $75 million upfront to acquire global rights to Simcere Pharmaceutical's experimental blood-cancer drug SIM0660. The deal could reach $1.53 billion if the drug meets development, regulatory and commercial milestones, with additional tiered royalties. The agreement grants Roche exclusive development, manufacturing and commercialisation rights outside Simcere's retained markets. The upfront payment represents just 4.9% of the deal's total potential value. SIM0660 remains in preclinical stages. Roche generated CHF11.9 billion in core operating profit during the first half of the year. The company's US-quoted shares fell to $53.55 on Tuesday following the announcement.

Yahoo Finance
Aug 25th, 2026
CVS and Roche stocks could benefit from expanding GLP-1 drug market

CVS Health and Roche could benefit from the growing GLP-1 drug market, alongside current leaders Eli Lilly and Novo Nordisk. CVS Health has improved its financial performance, with second-quarter revenue rising 7.3% year-over-year to $106.1 billion and adjusted earnings per share increasing 42.5% to $2.58. The pharmacy chain offers all approved GLP-1 medicines in the US, including Eli Lilly's Zepbound and Foundayo, plus Novo Nordisk's Wegovy. CVS also provides low-cost online consultations at $29 to assess patient eligibility for GLP-1 drugs. Beyond GLP-1 initiatives, CVS is addressing previous business challenges and is positioned to capitalise on rising healthcare spending in the US over the next decade.

Yahoo Finance
Aug 24th, 2026
Roche and Eli Lilly win FDA clearance for Alzheimer's blood test for over-55s

Roche and Eli Lilly have received FDA clearance for a blood test that helps detect signs of Alzheimer's disease in people aged 55 and older experiencing cognitive decline. The Elecsys pTau217 test measures a blood biomarker to determine whether patients are likely to have brain changes associated with Alzheimer's. The test can be performed using more than 4,500 Roche laboratory analysers already installed across the United States. Labcorp and Quest Diagnostics plan to offer the test through their laboratory networks, expanding access nationwide. Pricing has not been disclosed. The clearance follows European approval in May. Blood-based testing could provide a simpler alternative to existing methods like PET imaging and cerebrospinal fluid analysis, which can be expensive and invasive.